In fiscal 2026, which ended Jun 30, 2026, Integrated Biopharma, Inc. reported revenue of $43.9 million, down 19.3% from the year before. It recorded a net loss of $2.8 million. The operating loss came to $2.7 million, an operating margin of -6.2%. Diluted earnings per share were -$0.09. Across the 10 fiscal years shown, revenue shrank from $47.0 million in fiscal 2017 to $43.9 million in fiscal 2026, about 0.8% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
44
-19.3%
|
54
+8.0%
|
50
-0.7%
|
51
-9.9%
|
56
-11.5%
|
64
+20.4%
|
53
+5.6%
|
50
+14.3%
|
44
-6.9%
|
47
+11.2%
|
| Cost of revenue |
43
-11.7%
|
49
+5.1%
|
46
-0.4%
|
47
-6.2%
|
50
-8.1%
|
54
+17.5%
|
46
+5.2%
|
44
+13.0%
|
39
-3.9%
|
40
+9.7%
|
| Gross profit |
1
-85.6%
|
6
+43.2%
|
4
-4.4%
|
4
-38.0%
|
7
-30.9%
|
9
+40.9%
|
7
+8.1%
|
6
+24.7%
|
5
-25.2%
|
7
+21.1%
|
| Selling, general and administrative |
4
-1.0%
|
4
-2.5%
|
4
-7.8%
|
4
+3.5%
|
4
+3.0%
|
4
+6.6%
|
3
-1.4%
|
4
+6.8%
|
3
-5.3%
|
3
+2.7%
|
| Operating expenses |
4
-1.0%
|
4
-2.5%
|
4
-7.8%
|
4
+3.5%
|
4
+3.0%
|
4
+6.6%
|
3
-1.4%
|
4
+6.8%
|
3
-5.3%
|
3
+2.7%
|
| Operating income |
-3
-233.9%
|
2
+704.8%
|
0
+109.2%
|
0
-95.6%
|
3
-52.5%
|
6
+77.5%
|
3
+20.5%
|
3
+59.6%
|
2
-46.8%
|
3
+50.8%
|
| Other income (expense) |
0
+238.1%
|
0
+147.1%
|
0
+185.0%
|
-0
+86.5%
|
-0
-110.1%
|
1
+955.6%
|
-0
+74.2%
|
-1
+3.9%
|
-1
+48.2%
|
-1
-43.9%
|
| Pretax income |
-3
-224.3%
|
2
+669.4%
|
0
+168.0%
|
0
-96.1%
|
3
-64.2%
|
7
+134.7%
|
3
+51.2%
|
2
+103.2%
|
1
-45.9%
|
2
+56.1%
|
| Income tax |
0
-77.8%
|
1
+703.8%
|
0
+16.4%
|
0
+110.8%
|
-1
-62.0%
|
-1
+24.9%
|
-1
-388.1%
|
0
+8.6%
|
0
+166.5%
|
-0
-312.1%
|
| Net income |
-3
-451.7%
|
1
+621.4%
|
0
+429.4%
|
-0
-100.9%
|
4
-52.1%
|
8
+95.1%
|
4
+143.4%
|
2
+148.6%
|
1
-71.1%
|
2
+144.9%
|
| Basic EPS |
-0.09
-400.0%
|
0.03
|
0.00
|
0.00
-100.0%
|
0.13
-51.9%
|
0.27
+92.9%
|
0.14
+133.3%
|
0.06
+100.0%
|
0.03
-72.7%
|
0.11
+120.0%
|
| Diluted EPS |
-0.09
-400.0%
|
0.03
|
0.00
|
0.00
-100.0%
|
0.12
-52.0%
|
0.25
+92.3%
|
0.13
+116.7%
|
0.06
+200.0%
|
0.02
-80.0%
|
0.10
+100.0%
|
| Weighted average shares, basic |
31
+2.5%
|
30
+0.8%
|
30
+0.4%
|
30
+0.4%
|
30
+0.5%
|
30
+0.4%
|
30
+2.2%
|
29
+36.9%
|
21
+0.1%
|
21
+0.1%
|
| Weighted average shares, diluted |
31
-0.3%
|
31
+1.0%
|
31
+3.1%
|
30
-7.3%
|
32
+0.6%
|
32
+3.1%
|
31
+5.3%
|
30
-2.4%
|
30
+0.5%
|
30
+42.4%
|
| Other measures | ||||||||||
| Depreciation and amortization |
0
-7.9%
|
0
+3.6%
|
0
-12.5%
|
0
+4.5%
|
0
-0.3%
|
0
+8.0%
|
0
-2.8%
|
0
-7.8%
|
0
-11.5%
|
0
+12.0%
|
| EBITDA |
-2
-203.2%
|
2
+319.0%
|
1
+18.5%
|
0
-84.7%
|
3
-49.7%
|
6
+71.4%
|
4
+18.0%
|
3
+48.1%
|
2
-43.0%
|
4
+45.2%
|
| Interest coverage |
-225.42x
|
43.91x
|
4.83x
|
2.31x
|
21.45x
|
22.59x
|
8.21x
|
4.29x
|
1.83x
|
3.50x
|
| Margins | ||||||||||
| Gross margin |
1.82%
|
10.23%
|
7.72%
|
8.01%
|
11.65%
|
14.92%
|
12.75%
|
12.45%
|
11.41%
|
14.20%
|
| Operating margin |
-6.17%
|
3.72%
|
0.50%
|
0.24%
|
4.88%
|
9.10%
|
6.18%
|
5.41%
|
3.88%
|
6.79%
|
| Pretax margin |
-5.84%
|
3.79%
|
0.53%
|
0.20%
|
4.62%
|
11.40%
|
5.85%
|
4.09%
|
2.30%
|
3.95%
|
| Profit margin |
-6.48%
|
1.49%
|
0.22%
|
-0.07%
|
6.82%
|
12.61%
|
7.78%
|
3.38%
|
1.55%
|
5.00%
|
| EBITDA margin |
-5.50%
|
4.30%
|
1.11%
|
0.93%
|
5.48%
|
9.63%
|
6.77%
|
6.05%
|
4.67%
|
7.62%
|
| Effective tax rate |
—
|
60.81%
|
58.21%
|
134.00%
|
-47.79%
|
-10.57%
|
-33.03%
|
17.34%
|
32.44%
|
-26.40%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INBP (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hillside, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1016504
- Former names
- INTEGRATED HEALTH TECHNOLOGIES INC (until Apr 16, 2003); CHEM INTERNATIONAL INC (until May 14, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.